XY028-140 |
| カタログ番号GC62139 |
XY028-140 は、Cereblon と CDK のリガンドで接続された PROTAC です。 XY028-140 は、がん細胞の CDK4/6 発現と CDK4/6 活性の両方を阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2229974-83-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].
A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 µμ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 µμ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1].
[1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *